ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 105 filers reported holding ACLARIS THERAPEUTICS INC in Q2 2017. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $875,779 | +313.1% | 127,851 | +776.5% | 0.02% | +69.2% |
Q4 2021 | $212,000 | -10.9% | 14,587 | +7.6% | 0.01% | -35.0% |
Q2 2021 | $238,000 | -32.8% | 13,555 | -33.0% | 0.02% | -20.0% |
Q1 2018 | $354,000 | +43.3% | 20,222 | +111.1% | 0.02% | -59.7% |
Q3 2017 | $247,000 | +22.9% | 9,579 | +41.8% | 0.06% | +138.5% |
Q1 2017 | $201,000 | – | 6,755 | – | 0.03% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |